Biosimilar infliximab: short-term efficacy and safety following switch from originator
- At: 2017 FIP Congress in Seoul (South Korea)
- Type: Presentation
- By: MATULUKO, Ayodeji (University College London, School of Pharmacy, London, UK)
- Co-author(s): Ayodeji Benedicta Matuluko: School of Pharmacy, University College London, United Kingdom
Natalie Bidad: Department of Practice and Policy, School of Pharmacy, University College London, United Kingdom
Scott Mercer: Immunotherapy (Rheumatology, Dermatology, Allergy), Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
A retrospective/prospective evaluation with a convenience sample of 28 adults who had switched from originator to biosimilar infliximab, was conducted in a rheumatology clinic in London, United Kingdom. Data from patients’ records was collected from May to July 2016, including demographic characteristics, markers of clinical response and.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.